Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.
As part of MD Anderson’s commitment to bring our patients the most effective...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer Center have...
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from MD Andrerson Cancer Center. Retrospective analysis of clinical patient data suggests that beta blockers may slow or prevent the development of resistance to EGFR inhibitors.
The research, published today...
The largest analysis of metastatic melanoma patients who received a targeted therapy combination shows the treatment provides long-term survival...
A new-generation clinical trial for glioblastoma multiforme (GBM) — the deadliest form of brain cancer – will begin enrolling patients by...
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated...
An MD Anderson study may explain why chemotherapy drugs such as gemcitabine are ineffective against pancreatic cancer in some patients. The...
A team led by researchers at MD Anderson Cancer Center reports a crucial tumor-thwarting gene protects an immune attack against lung cancer...
Cetuximab, marketed as Erbitux®å, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients...